Bertrand Brieau1, Claire Auzolle2, Astrid Pozet3, David Tougeron4, Olivier Bouché5, Pauline Soibinet5, Romain Coriat6, Caroline Prieux2, Thierry Lecomte7, Gael Goujon8, Lysiane Marthey9, Philippe Rougier10, Franck Bonnetain3, Michel Ducreux2, Julien Taieb10, Aziz Zaanan11. 1. Gastroenterology and Digestive Oncology Department, Cochin University Hospital, APHP, Paris, France. 2. Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France. 3. Methodology and Quality of Life in Oncology Unit (EA 3181), Besançon University Hospital, Besançon, France. 4. Department of Gastroenterology, Poitiers University Hospital, Poitiers, France; Poitiers University, Laboratory "Inflammation, Tissus Epithéliaux et Cytokines EA 4331", Poitiers, France. 5. Department of Hepato-Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France. 6. Gastroenterology and Digestive Oncology Department, Cochin University Hospital, APHP, Paris, France; Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France. 7. Department of Gastroenterology, Tours University Hospital, Tours, France; Francois Rabelais University, Faculty of Medicine, Tours, France. 8. Gastroenterology and Digestive Oncology, Bichat Hospital, APHP, Paris, France. 9. Department of Gastroenterology and Digestive Oncology, Antoine Béclère Hospital, Clamart, APHP, France. 10. Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France; Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, APHP, Paris, France. 11. Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France; Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, APHP, Paris, France. Electronic address: aziz.zaanan@aphp.fr.
Abstract
BACKGROUND: Ovarian metastases from gastrointestinal tumours frequently lead to locoregional complications and undermine quality of life. The chemosensitivity of ovarian metastases from gastric cancer is unknown. AIM: To evaluate the efficacy of modern chemotherapy regimens in first-line treatment for patients with ovarian metastases from gastric cancer. METHODS: All consecutive patients with ovarian metastases from gastric cancer who received at least one cycle of chemotherapy were included in this retrospective study. RESULTS: Thirty-five patients were included (median age, 50.5 years; synchronous ovarian metastases, 60%). Seventeen patients (48.6%) underwent oophorectomy. Patients were treated with first-line chemotherapy based on platinum (n=14), irinotecan (n=8), taxane plus platinum (n=4) or epirubicin plus platinum (n=9). The median PFS and OS were 6.8 and 18.8 months, respectively. The objective response rate (ORR) for extra-ovarian (13.6%) and ovarian (20.9%) metastatic sites was not significantly different (p=0.55). There was no significant difference in terms of ORR on ovarian metastatic site according to the first-line chemotherapy (p=0.21). In multivariate analysis, oophorectomy was an independent prognostic factor for OS (p<0.01). CONCLUSIONS: This study suggests that ovarian metastases from gastric cancer are not more resistant than extra-ovarian metastases, and that oophorectomy is an independent prognostic factor significantly linked to OS. Prospective studies are needed to confirm these results.
BACKGROUND:Ovarian metastases from gastrointestinal tumours frequently lead to locoregional complications and undermine quality of life. The chemosensitivity of ovarian metastases from gastric cancer is unknown. AIM: To evaluate the efficacy of modern chemotherapy regimens in first-line treatment for patients with ovarian metastases from gastric cancer. METHODS: All consecutive patients with ovarian metastases from gastric cancer who received at least one cycle of chemotherapy were included in this retrospective study. RESULTS: Thirty-five patients were included (median age, 50.5 years; synchronous ovarian metastases, 60%). Seventeen patients (48.6%) underwent oophorectomy. Patients were treated with first-line chemotherapy based on platinum (n=14), irinotecan (n=8), taxane plus platinum (n=4) or epirubicin plus platinum (n=9). The median PFS and OS were 6.8 and 18.8 months, respectively. The objective response rate (ORR) for extra-ovarian (13.6%) and ovarian (20.9%) metastatic sites was not significantly different (p=0.55). There was no significant difference in terms of ORR on ovarian metastatic site according to the first-line chemotherapy (p=0.21). In multivariate analysis, oophorectomy was an independent prognostic factor for OS (p<0.01). CONCLUSIONS: This study suggests that ovarian metastases from gastric cancer are not more resistant than extra-ovarian metastases, and that oophorectomy is an independent prognostic factor significantly linked to OS. Prospective studies are needed to confirm these results.
Authors: Alice de Malet; Magali Svrcek; Anne Kerbaol; Nathalie Theou-Anton; Sandra Granier; Safi Dokmak; François Paye; Thierry André; Louis de Mestier; Jérôme Cros; Pascal Hammel Journal: Ther Adv Med Oncol Date: 2021-10-26 Impact factor: 8.168